Curis Non Current Liabilities Total Over Time
| CRIS Stock | USD 4.03 0.07 1.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Curis Performance and Curis Correlation. Curis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Curis. If investors know Curis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Curis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.77) | Revenue Per Share 1.759 | Quarterly Revenue Growth 0.159 | Return On Assets (0.46) | Return On Equity (3.73) |
The market value of Curis Inc is measured differently than its book value, which is the value of Curis that is recorded on the company's balance sheet. Investors also form their own opinion of Curis' value that differs from its market value or its book value, called intrinsic value, which is Curis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Curis' market value can be influenced by many factors that don't directly affect Curis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Curis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Curis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Curis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Liabilities Total Analysis
Compare Curis Inc and related stocks such as Aileron Therapeutics, Artelo Biosciences, and Histogen Non Current Liabilities Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALRN | 97.7 M | 97.7 M | 97.7 M | 97.7 M | 97.7 M | 97.7 M | 129.8 M | 0.0 | 5.3 M | 4.6 M | 219 K | 69 K | 1.8 M | 3.3 M | 3.2 M |
| ARTL | 12.9 K | 12.9 K | 12.9 K | 12.9 K | 12.9 K | 12.9 K | 12.9 K | 28.6 K | 529.3 K | 348.9 K | 490.2 K | 67 K | 23 K | 0.0 | 0.0 |
| HSTO | 1000 K | 1000 K | 1000 K | 1000 K | 1.1 M | 1.2 M | 21 M | 25.8 M | 2.9 M | 39.5 M | 5.3 M | 4.7 M | 4.5 M | 5.1 M | 4.9 M |
| XFOR | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 52.1 M | 14.9 M | 9 M | 22 M | 38.1 M | 38.7 M | 59.2 M | 73.3 M | 42.1 M |
| MREO | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 4.3 M | 24.2 M | 18.3 M | 16.3 M | 69.4 M | 25.9 M | 1.5 M | 6.5 M | 6.2 M |
| INZY | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 77.9 M | 1.3 M | 2.6 M | 6.1 M | 45.7 M | 25.2 M |
| TERN | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.7 M | 877 K | 947 K | 1.6 M | 1.2 M | 1.1 M |
| LPTX | 3.1 M | 3.1 M | 3.1 M | 70.5 M | 70.5 M | 70.5 M | 70.5 M | 11.9 M | 3.4 M | 711 K | 348 K | 37 K | 262 K | 0.0 | 0.0 |
| DAWN | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 92.2 M | 16 K | 408 K | 0.0 | 0.0 |
| PDSB | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 41 M | 3 M | 15 M | 17.4 M | 0.0 | 1.2 M | 490.4 K | 231.4 K | 23.2 M | 19.6 M | 10.4 M |
| ADAP | 556 K | 556 K | 3.5 M | 1 M | 14.3 M | 14.3 M | 28.1 M | 3.8 M | 5.4 M | 23.6 M | 70.8 M | 201 M | 182.5 M | 170.3 M | 178.8 M |
| PIRS | 474 | 474 | 474 | 4.9 M | 334 K | 23.9 K | 1.5 M | 46.6 M | 53.3 M | 62.7 M | 51.8 M | 52.2 M | 31 M | 35.6 M | 30.4 M |
| AFMD | 78.3 M | 78.3 M | 78.3 M | 90.8 M | 3.9 M | 3.1 M | 3.6 M | 4.1 M | 39.2 M | 38.5 M | 36.7 M | 24.6 M | 12.9 M | 13.4 M | 23.3 M |
| CRVS | 10 M | 10 M | 10 M | 10 M | 10 M | 126.5 M | 1.4 M | 971 K | 869 K | 2.3 M | 1.2 M | 2.6 M | 1.4 M | 0.0 | 0.0 |
| APTO | 145.1 K | 220.1 K | 1.2 M | 691.8 K | 486.6 K | 376.2 K | 0.0 | 0.0 | 1.3 M | 1 M | 535 K | 115 K | 1 M | 621 K | 590 K |
Curis Inc and related stocks such as Aileron Therapeutics, Artelo Biosciences, and Histogen Non Current Liabilities Total description
My Equities
My Current Equities and Potential Positions
| Curis Inc | CRIS |
| Classification | Cancer Fighters |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.03
Additional Tools for Curis Stock Analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.